Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Other Non-Current Liabilities (2023)

Kairos Pharma filings provide 1 years of Other Non-Current Liabilities readings, the most recent being $4000.0 for Q4 2023.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $4000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $4000.0, a N/A change, with the full-year FY2023 number at $4000.0, changed N/A from a year prior.
  • Other Non-Current Liabilities hit $4000.0 in Q4 2023 for Kairos Pharma.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $4000.0 in Q4 2023 to a low of $4000.0 in Q4 2023.